Support to regulatory authorities
First, the risk of contamination through blood-borne pathogens like HIV, hepatitis B and hepatitis C which cause life threatening diseases world wide. Second, the difficulties in validating quality assurance systems due to the inherent variability of biological products.
National Regulatory Authorities need to be competent, independent, with strong political backing and have clear authority to develop and enforce appropriate regulations. They also need to interact closely with medical and scientific institutions and civil society organizations representing health care users and professionals in the countries.
Unfortunately, the National Regulatory Authorities in many countries often do not have this type of professional structure. Efforts should therefore be made to strengthen technical capacity and expertise of National Regulatory Authorities worldwide. Technical and regulatory guidance is provided on main topics in this Web Site (see left side). Information is also available in the Recommendations made by the International Conference of Drug Regulatory Authorities (ICDRA) that has served, since 1980, as a global forum to meet and discuss ways of strengthening collaboration.
Focus areas
Meeting reports
This is the 66th situation report for the multi-country outbreak of mpox, which provides details on the global epidemiological situation for mpox, including...
In April 2026 (epidemiological weeks 14 to 17), a total of 20 100 new cholera and acute watery diarrhoea (AWD) cases were reported from 15 countries, territories,...
This is the eighth global public WHO situation report on the conflict in the Middle East. It covers the health situation and WHO operational updates from...
/epidemic-and-pandemic-preparedness-and-prevention-(epp)/global-influenza-programme-(gip)/global-respiratory-virus-activity-weekly-update.tmb-144v.png?sfvrsn=8b4f467c_2)
In week 20 2026, influenza positivity remained below 10% and SARS-CoV-2 activity remained low globally and in the northern hemisphere temperate and subtropical...
WHO Rapid Risk Assessment-Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo...
This Rapid Risk Assessment (RRA) aims to assess the risk of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda,...
/epidemic-and-pandemic-preparedness-and-prevention-(epp)/emerging-diseases-and-zoonoses-(ezd)/risk-assessment-rvf_0526.tmb-144v.png?sfvrsn=6e76d1a1_1)
Risk evaluation of Rift Valley Fever virus (RVFV) lineages and their public health impact
This risk evaluation summarizes current evidence on Rift Valley fever (RVF) virus, provides a risk evaluation based on the latest evidence, assesses the...
/health-systems-governance-and-financing-(hgf)/health-financing-(hef)/fr-sm31.tmb-144v.jpg?sfvrsn=59e2648f_1)
Le sous-module 3.1, « Délimitation des dépenses de santé », décrit la frontière des dépenses de santé,...
/health-systems-governance-and-financing-(hgf)/health-financing-(hef)/sp-sm31.tmb-144v.jpg?sfvrsn=af804949_1)
Submódulo 3.1: Frontera del gasto en salud
El submódulo 3.1, « Frontera del gasto en salud », describe el límite del gasto en salud, que define el contenido del gasto en...
/health-systems-governance-and-financing-(hgf)/health-financing-(hef)/ru-sm33.tmb-144v.jpg?sfvrsn=37a3f72b_1)
Подмодуль 3.3, «Основные правила Счетов Здравоохранения», излагает базовые правила учёта, применяемые при формировании Счетов Здравоохранения.
WHO publications